Présentation

Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States

“…13 However, data from Denmark have shown that the medication was not well tolerated in only 14% (4 of 29) of treated infants. 207 The main adverse effect was neutropenia, reported to occur more often with higher doses of P/S and especially when folinic acid was not administered.…”

“…207 The main adverse effect was neutropenia, reported to occur more often with higher doses of P/S and especially when folinic acid was not administered. 13 Moreover, seizures have been reported with cases of pyrimethamine overdose resulting from prescription dosing errors. 208 Adverse effects with pyrimethamine/ sulfadoxine (Fansidar, F. HoffmanLaRoche Ltd, Basel, Switzerland) were much less frequent, mainly skin rashes and urticarial reactions, and reported to occur in approximately 1% to 2% of cases.…”

“…Third, the evidence from some early key publications from cohorts of infants with CT whose mothers had not received antepartum treatment was also reviewed, because such older cohorts are more similar to the cohorts of children with CT still seen in the United States, where the majority of infants with CT are born to mothers without antepartum treatment. Fourth, we perused the systematic reviews already performed by the European Toxoprevention Study (EUROTOXO) group, the European Initiative for the study of CT on the following topics: (1) burden of disease from CT, 9 (2) evaluation of diagnostic performance of diagnostic tests for CT, 10 (3) assessment of postnatal treatment effects, 11 (4) strategies for the prevention of CT, 12 and (5) evaluation of adverse effects from antepartum and postnatal treatment of CT. 13 …”

“…208 Adverse effects with pyrimethamine/ sulfadoxine (Fansidar, F. HoffmanLaRoche Ltd, Basel, Switzerland) were much less frequent, mainly skin rashes and urticarial reactions, and reported to occur in approximately 1% to 2% of cases. 13 The disadvantage of the long halflife of sulfadoxine may need to be taken into account. Treatment discontinuations of pyrimethamine/ sulfadoxine attributable to adverse events in adults with Toxoplasma chorioretinitis have been reported to occur in up to 26% of patients.…”